Ivax, Purepac and KY Pharmaceutical Co. all received FDA approval to market doxazosin mesylate in 1 mg, 2 mg, 4 mg and 8 mg strengths. Doxazosin mesylate is indicated for treatment of benign prostatic hyperplasia and hypertension.
COPYRIGHT 2000 Lebhar-Friedman, Inc.
COPYRIGHT 2000 Gale Group